A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis

Trial Profile

A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms RA-BEYOND
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Feb 2018 Results of pooled analysis of NCT00902486, NCT01469013, NCT01185353, NCT01721044, NCT01721057, NCT01711359, NCT01710358 and NCT01885078 trials assessing the effects of baricitinib on the lipid profile, lipoprotein particle size and number, and GlycA published in the Annals of the Rheumatic Diseases
    • 11 Jan 2018 Planned End Date changed from 1 Dec 2021 to 1 Mar 2024.
    • 11 Jan 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Feb 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top